LAG-3 expression in distinct tumor-infiltrating lymphocyte (TIL) subpopulations, particularly in tumors with low MHC-II expression, may be critical for the development of a tolerogenic immune environment in classic Hodgkin lymphoma (cHL). This evidence concerns the gene LAG3 and neoplasm.